Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial.

de Castro N, Braun J, Charreau I, Lafeuillade A, Viard JP, Allavena C, Aboulker JP, Molina JM; EASIER ANRS 138 study group.

AIDS Res Ther. 2016 Apr 2;13:17. doi: 10.1186/s12981-016-0101-3. eCollection 2016.

2.

Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients.

Collins SE, Grant PM, Shafer RW.

Drugs. 2016 Jan;76(1):75-98. doi: 10.1007/s40265-015-0515-6.

3.

Factors That Affect Quality of Life among People Living with HIV Attending an Urban Clinic in Uganda: A Cohort Study.

Mutabazi-Mwesigire D, Katamba A, Martin F, Seeley J, Wu AW.

PLoS One. 2015 Jun 3;10(6):e0126810. doi: 10.1371/journal.pone.0126810. eCollection 2015.

4.

Long-term efficacy and safety of raltegravir in the management of HIV infection.

Liedtke MD, Tomlin CR, Lockhart SM, Miller MM, Rathbun RC.

Infect Drug Resist. 2014 Mar 18;7:73-84. doi: 10.2147/IDR.S40168. eCollection 2014. Review.

5.

Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years.

Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1066 Study Team.

Clin Infect Dis. 2014 Feb;58(3):413-22. doi: 10.1093/cid/cit696. Epub 2013 Oct 21.

6.

Inhibiting the HIV integration process: past, present, and the future.

Di Santo R.

J Med Chem. 2014 Feb 13;57(3):539-66. doi: 10.1021/jm400674a. Epub 2013 Sep 25. Erratum in: J Med Chem. 2014 Jul 24;57(14):6273.

7.

Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review.

Hernandez AV, Pasupuleti V, Deshpande A, Thota P, Collins JA, Vidal JE.

PLoS One. 2013 May 3;8(5):e63272. doi: 10.1371/journal.pone.0063272. Print 2013. Review.

8.

Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future.

Harris M, Nosyk B, Harrigan R, Lima VD, Cohen C, Montaner J.

AIDS Res Treat. 2012;2012:595762. doi: 10.1155/2012/595762. Epub 2012 Nov 8.

9.

Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials.

Flandre P.

PLoS One. 2011;6(9):e22871. doi: 10.1371/journal.pone.0022871. Epub 2011 Sep 7.

10.

Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.

Nachega JB, Mugavero MJ, Zeier M, Vitória M, Gallant JE.

Patient Prefer Adherence. 2011;5:357-67. doi: 10.2147/PPA.S22771. Epub 2011 Jul 18.

11.

Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy.

Charpentier C, Weiss L.

Infect Drug Resist. 2010;3:103-14. doi: 10.2147/IDR.S8673. Epub 2010 Oct 13.

12.

Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trial.

Goldwirt L, Braun J, de Castro N, Charreau I, Barrail-Tran A, Delaugerre C, Raffi F, Lascoux-Combe C, Aboulker JP, Taburet AM, Molina JM.

Antimicrob Agents Chemother. 2011 Jul;55(7):3613-5. doi: 10.1128/AAC.01827-10. Epub 2011 May 16.

13.

HIV-1 integrase inhibitor resistance and its clinical implications.

Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW.

J Infect Dis. 2011 May 1;203(9):1204-14. doi: 10.1093/infdis/jir025. Review.

14.

Authentic HIV-1 integrase inhibitors.

Liao C, Marchand C, Burke TR Jr, Pommier Y, Nicklaus MC.

Future Med Chem. 2010 Jul;2(7):1107-22. doi: 10.4155/fmc.10.199. Review.

15.

Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.

Gallien S, Delaugerre C, Charreau I, Braun J, Boulet T, Barrail-Tran A, de Castro N, Molina JM, Kuritzkes DR.

AIDS. 2011 Mar 13;25(5):665-9. doi: 10.1097/QAD.0b013e3283445834.

16.

High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.

Barau C, Delaugerre C, Braun J, de Castro N, Furlan V, Charreau I, Gérard L, Lascoux-Combe C, Molina JM, Taburet AM.

Antimicrob Agents Chemother. 2010 Feb;54(2):937-9. doi: 10.1128/AAC.01261-09. Epub 2009 Dec 7.

Items per page

Supplemental Content

Write to the Help Desk